CPX-351 improved overall survival among older patients with myelodysplastic-related AML who undergo hematopoietic transplantation. CPX-351 treatment resulted in improved overall survival (OS) among ...
Ashwin Kishtagari, MBBS, is Assistant Professor of Medicine in the division of hematology and oncology at Vanderbilt ...
Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors ...
Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of ...
Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results